111 research outputs found
Approaching the transit time limit for high-precision spectroscopy on metastable CO around 6 ÎĽm
We present a high-resolution spectroscopy experiment, based on a molecular beam setup, which pushes the measured line width close to the transit time limit, on the order of 100 kHz
Dynamically enhancing qubit-oscillator interactions with anti-squeezing
The interaction strength of an oscillator to a qubit grows with the
oscillator's vacuum field fluctuations. The well known degenerate parametric
oscillator has revived interest in the regime of strongly detuned squeezing,
where its eigenstates are squeezed Fock states. Owing to these amplified field
fluctuations, it was recently proposed that squeezing this oscillator would
dynamically boost its coupling to a qubit. In a superconducting circuit
experiment, we observe a two-fold increase in the dispersive interaction
between a qubit and an oscillator at 5.5 dB of squeezing, demonstrating in-situ
dynamical control of qubit-oscillator interactions. This work initiates the
experimental coupling of oscillators of squeezed photons to qubits, and
cautiously motivates their dissemination in experimental platforms seeking
enhanced interactions.Comment: 21 pages, 15 figure
Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study on 376 patients with superficial tumors
BACKGROUND:
Cutaneous metastases represent a therapeutic challenge. An increasing body of experience suggests that electrochemotherapy (ECT) provides effective tumor control, although its evidence basis should be strengthened.
METHODS:
This prospective, multicenter, observational study enrolled patients with superficial metastases, who underwent ECT at 10 centers between 2008 and 2013. Outcomes included adherence to European Standard Operating Procedures of ECT (ESOPE), tumor response, local progression-free survival (LPFS), toxicity and patient-reported outcomes (PROs, EORTC QLQ-C30 plus an 8-item questionnaire).
RESULTS:
We enrolled 376 eligible patients. Tumor histotype distribution was as follows: melanoma, 56%; squamous cell carcinoma, 11%; Kaposi sarcoma, 11%; breast carcinoma, 8%; basal cell carcinoma, 6%; soft tissue sarcomas, 3%; others, 5%. We registered 1304 target tumors (median size 1 cm). Treatment adhered to ESOPE in 88% of patients as to the route of drug administration, and in 70% as to electrode application. The procedure was mainly performed under sedation (64.6%) and by using intravenous chemotherapy (93.4%). Tumor response rate at 60 days was 88% (complete, 50%). Small tumor size predicted complete response achievement (OR 2.24, p = 0.003), higher LPFS (HR 0.68, p = 0.004) and improved PROs (Global Health Status, p < 0.001; wound bleeding, p < 0.001; healing, p = 0.002; and aesthetics, p < 0.001). Skin toxicity (grade 653, 7.8%) was lower in patients with tumors <2 cm (p 640.001). One-year LPFS was 73.7% (95%CI 68.4-78.3).
CONCLUSIONS:
ECT represents a valuable skin-directed therapy across a range of malignancies. The most frequently applied treatment modality is intravenous chemotherapy under sedation. Small tumor size predicts durable tumor control, fewer side-effects and better PROs
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third “Melanoma Research: “A bridge from Naples to the World” meeting, shortened as “Bridge Melanoma Meeting” took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients
- …